A randomized trial of memantine as treatment for spasticity in multiple sclerosis
Authors:
- Lahar R MehtaLMLahar R Mehta
- Steven R SchwidSSSteven R Schwid
- 22 December 2009
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 16 (2) , 248-251
Abstract
We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks. Eligible MS patients had to have an Ashworth spasticity rating of 2 or higher in at least one lower extremity muscle group. Subjects were randomized to receive either placebo or memantine 10 mg twice a day. The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study.Keywords
This publication has 8 references indexed in Scilit:
- Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)Brain, 2005
- Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trialThe Lancet, 2003
- Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic reviewMultiple Sclerosis Journal, 2002
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001
- Quantitative assessment of motor fatigue and strength in MSNeurology, 1999
- Development of a multiple sclerosis functional composite as a clinical trial outcome measureBrain, 1999
- (NMDA)-mediated muscle relaxant action of memantine in ratsNeuroscience Letters, 1992
- Effects of memantine on the twitch tension of mouse diaphragmEuropean Journal of Pharmacology, 1989